Cancer condition categories accounted for $378 million (48 percent) of the total increase in spending, with the largest increases for specified specialty drugs. (Photo: Shutterstock)
The use of very expensive specialty drugs is increasing—and so is the cost to employers, according to a research study by Prime Therapeutics LLC.
Prime's study analyzed the 2016-2018 pharmacy claims data of more 17 million commercially insured members, to identify the trends of "drug super spender" members, defined as those with greater than $250,000 in total drug cost per year. While still a small population—0.0275 percent of all members in 2018—the group's percentage of total drug spend is increasing—from 6.3 percent in 2016 to 8.6 percent in 2018, or roughly $2.1 billion in drug spend.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Katie Kuehner-Hebert
Katie Kuehner-Hebert is a freelance writer based in Running Springs, Calif. She has more than three decades of journalism experience, with particular expertise in employee benefits and other human resource topics.
